Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/12/17
End: 12/20/19
Due: 12/20/20
Phase: N/A
Priority: Normal
Start: 01/04/17
End: 05/24/17
Due: 05/24/18
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB | NCT03085758 | Adrenomed AG | user2@example.com | None | 2017-12-12 | 2019-12-20 | 2020-12-20 | - | - | 2025-07-14 |
| Adrecizumab-LPS Study | NCT03083171 | Adrenomed AG | user2@example.com | None | 2017-01-04 | 2017-05-24 | 2018-05-24 | - | - | 2025-07-14 |